| 1 |
33297669 |
10.3324/haematol.2020.267294 |
2022 |
Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas. |
BRAF |
| 2 |
33722842 |
10.1136/jclinpath-2020-207205 |
2022 |
Clinicopathological characteristic of ciliated muconodular papillary tumour of the lung. |
BRAF |
| 3 |
33952592 |
10.1136/jclinpath-2021-207597 |
2022 |
Adequacy of small biopsy and cytology specimens for comprehensive genomic profiling of patients with non-small-cell lung cancer to determine eligibility for immune checkpoint inhibitor and targeted therapy. |
BRAF |
| 4 |
34015890 |
10.4143/crt.2021.218 |
2022 |
Comparison of the Data of a Next-Generation Sequencing Panel from K-MASTER Project with That of Orthogonal Methods for Detecting Targetable Genetic Alterations. |
BRAF |
| 5 |
34309914 |
10.1111/jcpt.13489 |
2022 |
Advances in targeted therapy in non-small cell lung cancer with actionable mutations and leptomeningeal metastasis. |
BRAF |
| 6 |
34687488 |
10.1002/gcc.23005 |
2022 |
Clinicopathological features and resistance mechanisms in HIP1-ALK-rearranged lung cancer: A multicenter study. |
BRAF |
| 7 |
34704312 |
10.1111/cas.15176 |
2022 |
Real-world data on NGS using the Oncomine DxTT for detecting genetic alterations in non-small-cell lung cancer: WJOG13019L. |
BRAF |
| 8 |
34710243 |
10.1002/ajh.26390 |
2022 |
Hairy cell leukemia 2022: Update on diagnosis, risk-stratification, and treatment. |
BRAF |
| 9 |
34802044 |
10.1038/s41379-021-00954-z |
2022 |
A novel diagnostic approach for the classification of small B-cell lymphoid neoplasms based on the NanoString platform. |
BRAF |
| 10 |
34843129 |
10.1111/his.14603 |
2022 |
ALK rearrangements in infantile fibrosarcoma-like spindle cell tumours of soft tissue and kidney. |
BRAF |
| 11 |
34952945 |
10.1038/s41379-021-01002-6 |
2022 |
Genomic landscape of Epstein-Barr virus-positive extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue. |
BRAF |
| 12 |
35012520 |
10.1186/s12890-021-01803-0 |
2022 |
Global prognostic impact of driver genetic alterations in patients with lung adenocarcinoma: a real-life study. |
BRAF |
| 13 |
35064935 |
10.1111/his.14619 |
2022 |
Parallel evolution of two distinct lymphoid proliferations in clonal haematopoiesis. |
BRAF |
| 14 |
35076701 |
10.1001/jamanetworkopen.2021.44923 |
2022 |
Trends in Prices of Drugs Used to Treat Metastatic Non-Small Cell Lung Cancer in the US From 2015 to 2020. |
BRAF |
| 15 |
35092381 |
10.31557/APJCP.2022.23.1.131 |
2022 |
Correlation between Programmed Death Ligand-1(PD-L1) Expression and Driver Gene Mutations in Non-Small Cell Lung Carcinoma- Adenocarcinoma Phenotype. |
BRAF |
| 16 |
35147461 |
10.1177/00369330221078995 |
2022 |
Evaluation of lung cancer biomarkers profile for the decision of targeted therapy in EBUS-TBNA cytological samples. |
BRAF |
| 17 |
35189530 |
10.1016/j.ctarc.2022.100522 |
2022 |
Real-world patterns of biomarker testing and targeted therapy in de novo metastatic non-small cell lung cancer patients in the US oncology network. |
BRAF |
| 18 |
35205796 |
10.3390/cancers14041050 |
2022 |
Immunophenotypic Analysis of Hairy Cell Leukemia (HCL) and Hairy Cell Leukemia-like (HCL-like) Disorders. |
BRAF |
| 19 |
35234079 |
10.1177/10668969221081432 |
2022 |
Hairy Cell Leukemia-Japanese Variant: Report of a Patient and Literature Review. |
BRAF |
| 20 |
35322197 |
10.1038/s41388-022-02266-1 |
2022 |
Discoidin Domain Receptor 2 orchestrates melanoma resistance combining phenotype switching and proliferation. |
BRAF |
| 21 |
35353542 |
10.1126/scitranslmed.abc7480 |
2022 |
Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells. |
BRAF |
| 22 |
35356636 |
10.14740/jh942 |
2022 |
Concurrent Presentation of Hairy Cell Leukemia and Mantle Cell Lymphoma (Leukemic Non-Nodal Variant): An Extremely Rare Composite Lymphoma. |
BRAF |
| 23 |
35359040 |
10.3760/cma.j.cn112151-20211220-00915 |
2022 |
[Clinicopathological features and BRAF V600E and MYD88 L265P mutation status of nodal marginal zone lymphoma]. |
BRAF |
| 24 |
35363510 |
10.1200/JCO.21.02840 |
2022 |
Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial. |
BRAF |
| 25 |
35373885 |
10.1002/pbc.29575 |
2022 |
Retrospective and integrative analyses of molecular characteristics and their specific imaging parameters in pediatric grade 1 gliomas. |
BRAF |
| 26 |
35437610 |
10.1007/s00277-022-04795-x |
2022 |
Purine nucleoside analogs plus rituximab are an effective treatment choice for hairy cell leukemia-variant. |
BRAF |
| 27 |
35450208 |
10.1177/20406207221090886 |
2022 |
Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib. |
BRAF |
| 28 |
35454811 |
10.3390/cancers14081904 |
2022 |
Deciphering Genetic Alterations of Hairy Cell Leukemia and Hairy Cell Leukemia-like Disorders in 98 Patients. |
BRAF |
| 29 |
35543076 |
10.1111/his.14680 |
2022 |
Histologic characterization of paediatric mesenchymal neoplasms treated with kinase-targeted therapy. |
BRAF |
| 30 |
35582532 |
10.20517/cdr.2021.85 |
2022 |
Efficacy of ICIs on patients with oncogene-driven non-small cell lung cancer: a retrospective study. |
BRAF |
| 31 |
35663079 |
10.12998/wjcc.v10.i14.4541 |
2022 |
Bronchiolar adenoma with unusual presentation: Two case reports. |
BRAF |
| 32 |
35669427 |
10.3389/fonc.2022.873111 |
2022 |
Economic Analysis of Tissue-First, Plasma-First, and Complementary NGS Approaches for Treatment-Naïve Metastatic Lung Adenocarcinoma. |
BRAF |
| 33 |
35739536 |
10.1186/s12920-022-01291-z |
2022 |
A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib. |
BRAF |
| 34 |
35748237 |
10.2217/pme-2021-0059 |
2022 |
Targeting molecular alterations in non-small-cell lung cancer: what's next? |
BRAF |
| 35 |
35774685 |
10.7759/cureus.25405 |
2022 |
A Rare Case of Metachronous Quadruple Primary Malignancies in a Single Patient: A Case Report and Comprehensive Literature Review. |
BRAF |
| 36 |
35789115 |
10.1111/his.14718 |
2022 |
Hodgkinoid histiocytosis: an atypical nodal CD30 and S100-positive histiocytosis with eosinophilia. |
BRAF |
| 37 |
35806042 |
10.3390/ijms23137037 |
2022 |
State-of-the-Art Molecular Oncology of Lung Cancer in Taiwan. |
BRAF |
| 38 |
35870258 |
10.1016/j.lungcan.2022.07.011 |
2022 |
Genetic correlation of crizotinib efficacy and resistance in ALK- rearranged non-small-cell lung cancer. |
BRAF |
| 39 |
35900506 |
10.4103/ijpm.ijpm_621_21 |
2022 |
Novel ALK-EML4 fusion with prominent mucous and hyaline stroma: Expanding the molecular genetic spectrum of S100 and CD34 positive spindle cell tumor. |
BRAF |
| 40 |
35900560 |
10.4103/jcrt.JCRT_559_20 |
2022 |
Primary pulmonary epithelial-myoepithelial carcinoma: Report of a rare and under-diagnosed low-grade malignancy. |
BRAF |
| 41 |
35980949 |
10.1371/journal.pone.0273207 |
2022 |
Various impacts of driver mutations on the PD-L1 expression of NSCLC. |
BRAF |
| 42 |
35984185 |
10.1097/MD.0000000000030094 |
2022 |
Response to treatment with an ALK-TKI in a patient with advanced lung adenocarcinoma with concurrent ALK fusion and high PD-L1 expression: A case report. |
BRAF |
| 43 |
35988454 |
10.1016/j.esmoop.2022.100560 |
2022 |
Diagnostic work-up and systemic treatment for advanced non-squamous non-small-cell lung cancer in four Southeast Asian countries. |
BRAF |
| 44 |
36051021 |
10.1002/jha2.486 |
2022 |
Lymphoma-associated acquired von Willebrand syndrome responsive to splenectomy: A case report. |
BRAF |
| 45 |
32273478 |
10.3324/haematol.2020.251579 |
2021 |
Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma. |
BRAF |
| 46 |
32638211 |
10.1007/s12020-020-02411-4 |
2021 |
Diagnostic and prognostic value of a 7-panel mutation testing in thyroid nodules with indeterminate cytology: the SWEETMAC study. |
BRAF |
| 47 |
32815748 |
10.1080/0284186X.2020.1806358 |
2021 |
Different expression of BRAFV600E, ALK and PD-L1 in melanoma in children and adolescents: a nationwide retrospective study in Finland in 1990-2014. |
BRAF |
| 48 |
32915318 |
10.1007/s00262-020-02714-5 |
2021 |
Toxicity with small molecule and immunotherapy combinations in non-small cell lung cancer. |
BRAF |
| 49 |
32929178 |
10.1038/s41379-020-00673-x |
2021 |
The mutational landscape of histiocytic sarcoma associated with lymphoid malignancy. |
BRAF |
| 50 |
32943371 |
10.1016/j.clml.2020.08.007 |
2021 |
Highlights of the Management of Adult Histiocytic Disorders: Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Rosai-Dorfman Disease, and Hemophagocytic Lymphohistiocytosis. |
BRAF |
| 51 |
32954834 |
10.1080/17425247.2021.1825377 |
2021 |
Targeted drug therapy in non-small cell lung cancer: Clinical significance and possible solutions-Part I. |
BRAF |
| 52 |
32969291 |
10.1080/10428194.2020.1824070 |
2021 |
The triptych of mixed histiocytosis: a systematic review of 105 cases and proposed clinical classification. |
BRAF |
| 53 |
32970929 |
10.1111/ajco.13449 |
2021 |
Role and mechanism of autophagy-regulating factors in tumorigenesis and drug resistance. |
BRAF |
| 54 |
33068418 |
10.1093/neuonc/noaa233 |
2021 |
Population-based estimates of survival among elderly patients with brain metastases. |
BRAF |
| 55 |
33237469 |
10.1007/s00428-020-02971-w |
2021 |
ALK alterations in salivary gland carcinomas. |
BRAF |
| 56 |
33360690 |
10.1016/j.jss.2020.11.012 |
2021 |
Thyroid Cancer Identified After Positron Emission Tomography (PET) Shows Aggressive Histopathology. |
BRAF |
| 57 |
33387037 |
10.1007/s00432-020-03491-5 |
2021 |
Kinase gene fusions: roles and therapeutic value in progressive and refractory papillary thyroid cancer. |
BRAF |
| 58 |
33506327 |
10.1007/s00428-021-03032-6 |
2021 |
Undifferentiated large cell/rhabdoid carcinoma presenting in the intestines of patients with concurrent or recent non-small cell lung cancer (NSCLC): clinicopathologic and molecular analysis of 14 cases indicates an unusual pattern of dedifferentiated metastases. |
BRAF |
| 59 |
33552685 |
10.1080/2162402X.2020.1865653 |
2021 |
Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data. |
BRAF |
| 60 |
33591844 |
10.1200/JCO.20.03570 |
2021 |
Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update. |
BRAF |
| 61 |
33637515 |
10.1136/bcr-2021-241815 |
2021 |
Rare case of <i>BRAF V600E</i> mutant anaplastic pleomorphic xanthroastrocytoma in a 5-year survivor of acute lymphoblastic leukaemia. |
BRAF |
| 62 |
33650659 |
10.3892/or.2020.7911 |
2021 |
Potentially life‑threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors (Review). |
BRAF |
| 63 |
33663128 |
10.1097/MD.0000000000024917 |
2021 |
BRAF V600E mutation as a novel mechanism of acquired resistance to ALK inhibition in ALK-rearranged lung adenocarcinoma: A case report. |
BRAF |
| 64 |
33671873 |
10.3390/cancers13040804 |
2021 |
Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations. |
BRAF |
| 65 |
33676171 |
10.1016/j.anndiagpath.2021.151720 |
2021 |
From the archives of MD Anderson Cancer Center: A case of concurrent follicular lymphoma and Langerhans cell sarcoma with a review of the literature. |
BRAF |
| 66 |
33685720 |
10.1016/j.pathol.2021.01.002 |
2021 |
New developments in non-Hodgkin lymphoid malignancies. |
BRAF |
| 67 |
33706747 |
10.1186/s12887-021-02590-7 |
2021 |
Giant congenital nodular melanoma in a newborn: a case report and literature review. |
BRAF |
| 68 |
33722699 |
10.1016/j.critrevonc.2021.103299 |
2021 |
Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake. |
BRAF |
| 69 |
33728131 |
10.7759/cureus.13112 |
2021 |
Pancoast-Tobias Syndrome: A Unique Presentation of Lung Cancer. |
BRAF |
| 70 |
33735913 |
10.1182/blood.2020010137 |
2021 |
A rapid genotyping panel for detection of primary central nervous system lymphoma. |
BRAF |
| 71 |
33777766 |
10.3389/fonc.2021.620435 |
2021 |
Case Report: Multiple Chromosomal Translocations Including Novel CIITA-CREBBP Fusion and Mutations in a Follicular Lymphoma. |
BRAF |
| 72 |
33807876 |
10.3390/ijms22052625 |
2021 |
Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer. |
BRAF |
| 73 |
33811006 |
10.1016/j.clml.2021.02.005 |
2021 |
Inhibitor of BRAF<sup>V600E</sup> Mutation as a Treatment Option for Hairy Cell Leukemia With Deep Neutropenia and Infectious Complications. |
BRAF |
| 74 |
33833885 |
10.1155/2021/6680635 |
2021 |
A Dose-Response Relationship to Radiotherapy for Cutaneous Lesions of Langerhans Cell Histiocytosis. |
BRAF |
| 75 |
33872472 |
10.1002/cncy.22434 |
2021 |
Actionable driver DNA variants and fusion genes can be detected in archived cytological specimens with the Oncomine Dx Target Test Multi-CDx system in lung cancer. |
BRAF |
| 76 |
33889528 |
10.21037/tlcr-20-1113 |
2021 |
A narrative review of MET inhibitors in non-small cell lung cancer with <i>MET</i> exon 14 skipping mutations. |
BRAF |
| 77 |
33895683 |
10.1016/j.ejca.2021.03.026 |
2021 |
Computed tomography-guided biopsy of radiologically unclear lesions in advanced skin cancer: A retrospective analysis of 47 cases. |
BRAF |
| 78 |
33898318 |
10.3389/fonc.2021.647598 |
2021 |
Profiling Oncogenic Germline Mutations in Unselected Chinese Lung Cancer Patients. |
BRAF |
| 79 |
33939500 |
10.1177/10668969211013402 |
2021 |
A Pedigree Analysis and Clonal Correlations of the Coexistence of B-Cell Lymphoma and Histiocytic/Dendritic Cell Tumor. |
BRAF |
| 80 |
33979489 |
10.1056/NEJMoa2031298 |
2021 |
Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia. |
BRAF |
| 81 |
34009369 |
10.1210/clinem/dgab304 |
2021 |
Afirma Genomic Sequencing Classifier and Xpression Atlas Molecular Findings in Consecutive Bethesda III-VI Thyroid Nodules. |
BRAF |
| 82 |
34058070 |
10.1002/1878-0261.13033 |
2021 |
NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment. |
BRAF |
| 83 |
34187757 |
10.1016/j.cllc.2021.05.006 |
2021 |
Understanding Contemporary Molecular Biomarker Testing Rates and Trends for Metastatic NSCLC Among Community Oncologists. |
BRAF |
| 84 |
34198843 |
10.3390/ijms22116099 |
2021 |
Molecular Characterization of a Rare Case of Bilateral Vitreoretinal T Cell Lymphoma through Vitreous Liquid Biopsy. |
BRAF |
| 85 |
34275772 |
10.1016/j.clml.2021.06.007 |
2021 |
Management of Relapsed Hairy Cell Leukemia: A Systematic Review of Novel Agents and Targeted Therapies. |
BRAF |
| 86 |
34298439 |
10.1016/j.prp.2021.153551 |
2021 |
Driver and novel genes correlated with metastasis of non-small cell lung cancer: A comprehensive analysis. |
BRAF |
| 87 |
34337566 |
10.1016/j.xcrm.2021.100350 |
2021 |
ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors. |
BRAF |
| 88 |
34343999 |
10.1159/000514821 |
2021 |
Multigene Combined Detection by RT-qPCR Using Cytological Specimens. |
BRAF |
| 89 |
34353680 |
10.1016/j.lungcan.2021.06.002 |
2021 |
The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer. |
BRAF |
| 90 |
34392186 |
10.1016/j.ejca.2021.06.043 |
2021 |
Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing. |
BRAF |
| 91 |
34466010 |
10.2147/CCID.S323865 |
2021 |
Reactive Langerhans Cell Proliferation Mimicking Langerhans Cell Histiocytosis in Association with Sézary Syndrome: A Case Report and Literature Review. |
BRAF |
| 92 |
34570179 |
10.1182/bloodadvances.2021004668 |
2021 |
Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies. |
BRAF |
| 93 |
34593218 |
10.1016/j.bulcan.2021.06.009 |
2021 |
[Molecular genotyping in refractory thyroid cancers in 2021: When, how and why? A review from the TUTHYREF network]. |
BRAF |
| 94 |
34804000 |
10.3389/fimmu.2021.686057 |
2021 |
Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma. |
BRAF |
| 95 |
35116717 |
10.21037/tcr-21-1037 |
2021 |
Molecular typing of lung adenocarcinoma with computed tomography and CT image-based radiomics: a narrative review of research progress and prospects. |
BRAF |
| 96 |
36045702 |
10.37349/etat.2021.00056 |
2021 |
A review of molecularly targeted therapy in biliary tract carcinoma: what is the next step? |
BRAF |
| 97 |
31439678 |
10.3324/haematol.2019.230375 |
2020 |
Genomic profiling of primary histiocytic sarcoma reveals two molecular subgroups. |
BRAF |
| 98 |
31598903 |
10.1007/s12094-019-02218-4 |
2020 |
Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. |
BRAF |
| 99 |
31715289 |
10.1016/j.pharmthera.2019.107438 |
2020 |
Drug resistance to targeted therapeutic strategies in non-small cell lung cancer. |
BRAF |
| 100 |
31747139 |
10.1002/cam4.2670 |
2020 |
A community-based lung cancer rapid tissue donation protocol provides high-quality drug-resistant specimens for proteogenomic analyses. |
BRAF |
Datasets
Models
